Suchergebnisse - "Reid, Tony"

PubPharm (15)

1

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats

enthalten in: International journal of medical sciences | 2022

von Caroen, S. | Oronsky, B. | Reid, T. | +2

2

Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas

enthalten in: Journal of drug targeting | 2021

von Oronsky, B. | Reid, T. | Cabrales, P.

3

Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

enthalten in: Journal of medicinal chemistry | 2021

von Oronsky, B. | Guo, X. | Wang, X. | +9

4

RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia

enthalten in: Expert opinion on drug metabolism & toxicology | 2021

von Oronsky, B. | Cabrales, P. | Caroen, S. | +4

5

Desperate Times, Desperate Measures : The Case for RRx-001 in the Treatment of COVID-19

enthalten in: Seminars in oncology | 2020

von Oronsky, B. | Knox, S. | Cabrales, P. | +2

6

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

enthalten in: Oncoimmunology | 2020

von Oronsky, B. | Carter, C. | Caroen, S. | +3

7

REPLATINUM Phase III randomized study : RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

enthalten in: Future oncology (London, England) | 2019

von Oronsky, B. | Reid, T. | Larson, C. | +12

8

RRx-001 protects against cisplatin-induced toxicities

enthalten in: Journal of cancer research and clinical oncology | 2017

von Oronsky, B. | Reid, T. | Larson, C. | +4

9

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

enthalten in: Expert review of hematology | 2017

von Cabrales, P. | Caroen, S. | Oronsky, A. | +7

10

RRx-001 : a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

enthalten in: Expert opinion on investigational drugs | 2017

von Oronsky, B. | Paulmurugan, R. | Foygel, K. | +18

ErratumIn: Expert Opin Investig Drugs. 2017 Feb;26(2):261 Carterg, Corey A [corrected to Carter, Corey A]. - PMID 28054500